C WorldWide Group Holding A S Sells 42,955 Shares of Shire PLC (SHPG)
C WorldWide Group Holding A S lowered its stake in Shire PLC (NASDAQ:SHPG) by 37.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,845 shares of the biopharmaceutical company’s stock after selling 42,955 shares during the period. C WorldWide Group Holding A S’s holdings in Shire PLC were worth $11,874,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. HPM Partners LLC bought a new position in Shire PLC during the first quarter valued at approximately $1,534,000. Vanguard Group Inc. raised its position in Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the period. BlackRock Inc. raised its position in Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the period. Laurion Capital Management LP bought a new position in Shire PLC during the first quarter valued at approximately $10,611,000. Finally, Gabelli Funds LLC raised its position in Shire PLC by 1,000.0% in the first quarter. Gabelli Funds LLC now owns 16,500 shares of the biopharmaceutical company’s stock valued at $2,875,000 after buying an additional 15,000 shares during the period. 21.04% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ:SHPG) opened at 149.97 on Friday. Shire PLC has a one year low of $149.75 and a one year high of $209.22. The company has a market capitalization of $44.67 billion, a P/E ratio of 67.10 and a beta of 1.60. The stock has a 50 day moving average price of $164.82 and a 200-day moving average price of $172.65.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping the Zacks’ consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company had revenue of $3.75 billion during the quarter. During the same quarter in the prior year, the business posted $3.38 EPS. Shire PLC’s revenue was up 54.2% compared to the same quarter last year. Equities research analysts predict that Shire PLC will post $14.93 earnings per share for the current fiscal year.
SHPG has been the topic of several recent research reports. Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Sanford C. Bernstein lowered Shire PLC from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $209.22 to $161.09 in a research report on Thursday, May 25th. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, HSBC Holdings plc lowered Shire PLC from a “hold” rating to a “reduce” rating in a research report on Friday, May 19th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $222.27.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.